Credit Suisse AG Boosts Stake in Theravance Biopharma, Inc. (NASDAQ:TBPH)

Credit Suisse AG lifted its holdings in shares of Theravance Biopharma, Inc. (NASDAQ:TBPH) by 59.6% during the first quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 159,943 shares of the biopharmaceutical company’s stock after acquiring an additional 59,718 shares during the quarter. Credit Suisse AG owned 0.25% of Theravance Biopharma worth $1,735,000 as of its most recent filing with the SEC.

Several other institutional investors have also modified their holdings of the business. Principal Financial Group Inc. purchased a new position in shares of Theravance Biopharma during the 1st quarter valued at approximately $101,000. Acadian Asset Management LLC boosted its stake in Theravance Biopharma by 51.6% during the 1st quarter. Acadian Asset Management LLC now owns 8,277 shares of the biopharmaceutical company’s stock valued at $77,000 after acquiring an additional 2,818 shares during the last quarter. Vanguard Group Inc. grew its holdings in Theravance Biopharma by 10.3% during the 1st quarter. Vanguard Group Inc. now owns 6,947,947 shares of the biopharmaceutical company’s stock worth $66,421,000 after acquiring an additional 648,124 shares in the last quarter. Charles Schwab Investment Management Inc. increased its position in shares of Theravance Biopharma by 3.1% in the 1st quarter. Charles Schwab Investment Management Inc. now owns 402,640 shares of the biopharmaceutical company’s stock worth $3,850,000 after purchasing an additional 12,095 shares during the last quarter. Finally, UBS Group AG increased its position in shares of Theravance Biopharma by 45.0% in the 1st quarter. UBS Group AG now owns 3,549 shares of the biopharmaceutical company’s stock worth $34,000 after purchasing an additional 1,101 shares during the last quarter. Institutional investors and hedge funds own 99.10% of the company’s stock.

Theravance Biopharma Price Performance

Shares of TBPH opened at $9.52 on Wednesday. Theravance Biopharma, Inc. has a 12 month low of $9.00 and a 12 month high of $12.03. The stock has a fifty day moving average price of $9.85 and a 200 day moving average price of $10.49. The company has a market cap of $502.75 million, a P/E ratio of 0.84 and a beta of 0.43.

Theravance Biopharma (NASDAQ:TBPH) last released its quarterly earnings results on Monday, August 7th. The biopharmaceutical company reported ($0.28) EPS for the quarter, missing the consensus estimate of ($0.22) by ($0.06). The firm had revenue of $13.75 million for the quarter, compared to the consensus estimate of $15.24 million. Theravance Biopharma had a negative return on equity of 16.88% and a net margin of 1,694.17%. As a group, research analysts anticipate that Theravance Biopharma, Inc. will post -1.06 earnings per share for the current year.

Analyst Ratings Changes

TBPH has been the topic of several research reports. StockNews.com assumed coverage on Theravance Biopharma in a research note on Thursday, August 17th. They set a “hold” rating on the stock. HC Wainwright restated a “buy” rating and set a $20.00 price objective on shares of Theravance Biopharma in a research note on Tuesday, August 8th.

Theravance Biopharma Profile

Theravance Biopharma, Inc is a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small molecule drugs designed to better meet patient needs. Its research is focused in the areas of inflammation and immunology.
In pursuit of its purpose, Theravance Biopharma applies insights and innovation at each stage of its business and utilizes its internal capabilities and those of partners around the world.